What's Going On With GT Biopharma?
GT Biopharma (GTBP) today announced that the United States Patent and Trademark Office (USPTO) has issued the firm two new patents for its TriKE® protein biologic technology platform. Shares of the company were trading higher 3.49% to $8.61 a share on Thursday.
What Does This Mean For GT Biopharma?
The two patents appear to cover the company's pipeline of clinical and non-clinical product candidates made up of tri-specific killer engagers that are meant to target natural killer cells and induce NK cell activation at that site. Both patents are ultimately target antigens, although one is meant specifically for HIV antigens.
"2021 has been an exciting year for GT Biopharma as we reported positive, interim data results from our first-in-human GTB-3550 TriKE® Phase I clinical trial for the treatment of refractory/relapsed acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). As such, we are delighted that these newly granted patents have secured the broad IP rights underpinning the TriKE® technology platform. The granting of these patents provide us the necessary protection to continue to expand our clinical development path forward," said Anthony Cataldo, Chairman and CEO.
GTBP has a Fundamental Rank of 85. Find out what this means to you and get the rest of the rankings on GTBP!
GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
